Almirall to Present New Drug Data at EADV

Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), the company announced.

The EADV takes place September 25-28 in Amsterdam, Netherlands. In addition to the abstracts, Almirall will host two satellite symposia, on psoriasis and atopic dermatitis, providing a platform for experts to discuss current data, share insights, and facilitate discussions about the treatment of these chronic conditions with advanced biologics.

As part of their presentations, Almirall will unveil new interim data on the treatment of adults with moderate-to-severe plaque psoriasis with tidrakizumab at 52 weeks from the POSITIVE clinical study. The POSITIVE study is the first clinical trial in dermatology to use the WHO-5 Wellbeing Index as a primary endpoint. The five-item World Health Organization Wellbeing Index is a validated questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases. The different sub-analyses presented during the congress reinforce the effectiveness of tildrakizumab on signs and symptoms in skin and beyond.

Almirall will also present new data on lebrikizumab, a biologic approved for the treatment of moderate-to-severe atopic dermatitis. The late-breaking presentation will report lebrikizumab’s data over 3 years of continuous treatment, alongside new data on the rates of absolute endpoints and its effectiveness in patients inadequately controlled or ineligible for cyclosporine.